All eyes are on the next wave of CAR and TCR innovation. Success is no longer defined by clinical wins alone, but by smarter biological design, delivery strategies and manufacturing breakthroughs to lower COGs, expand patient access and secure commercial viability.

With this, we're thrilled to share the brand-new agenda for the 11th CAR-TCR Summit, returning to Boston September 15-17! 

You can view the 3-day program here.

Crafted in collaboration with industry veterans and spanning four tracks across the entire development life cycle, the program offers a clear, strategic view of the next era of cell therapy.

Expect first hand insight into cutting-edge in vivo and next generation CAR and TCR innovations, hear unpublished clinical data across emerging indications, and learn from real world automated manufacturing case studies shaping commercial readiness.

Beyond the science, you'll gain direct access to investors to align on where capital and strategic partnerships are moving next, complemented by high-value networking with C-suite executives and academic KOLs to safegaurd every stage of your cell therapy development pipeline.

Here's first look at some of the expert speakers leading these conversations:

• Nikhil Mutyal, Global Head of Search & Evaluation, Respiratory & Immunology, AstraZeneca
• Ilya Yasny, Partner, LanceBio Ventures/Bioptic
• Ruth Salmon, Vice President, Preclinical Sciences, Bristol Myers Squibb
• Adrian Kilcoyne, Chief Medical Officer, Cellectis
• Koji Yasunda, Principal, Fast Track Initiative
• Chris Crowell, Global Head, Manufacturing, Kite Pharma
• Helen Sabzevari, President & Chief Executive Officer, Precigen

You can view the full list of our 75+ expert speakers and their sessions in the agenda.

If you're committed to driving the innovation and commercial readiness needed to make CAR-T therapies safer, more effective, scalable, and accessible to the patients who need them most, then this is the meeting for you.